SV-IV Peptide 1–16 Reduces Coagulant Power in Factor V and Factor V Leiden
Author Information
Author(s): Biagio Di Micco, Marilena Lepretti, Lidia Rota, Ilaria Quaglia, Paola Ferrazzi, Gianluca Di Micco, Pierpaolo Di Micco
Primary Institution: University of Sannio Benevento, Italy
Hypothesis
Can SV-IV Peptide 1–16 inhibit the procoagulant activity of normal Factor V or Factor V Leiden?
Conclusion
SV-IV Peptide 1–16 effectively reduces the coagulation capacity of both normal Factor V and Factor V Leiden in vitro.
Supporting Evidence
- Peptide 1–16 significantly increased coagulation times in both normal and Leiden plasma.
- The study demonstrated a more than 50% reduction in lysis of Chromozym X by Factor Xa when Peptide 1–16 was present.
- Statistical analysis showed significant differences in coagulation times with p-values less than 0.001.
Takeaway
A special peptide can help slow down blood clotting in people with certain blood conditions.
Methodology
The study involved incubating SV-IV Peptide 1–16 with plasma samples from patients with Factor V Leiden and measuring coagulation times.
Potential Biases
Potential bias due to the small sample size and the specific patient population.
Limitations
The study used purified Factor V and did not have access to purified Factor V Leiden for testing.
Participant Demographics
Twelve patients, carriers of Factor V Leiden, with most having a history of thrombotic disease.
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website